Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 228

1.

Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer.

von Pawel J, Jotte R, Spigel DR, O'Brien ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts K, Trigo JM, Clingan P, Schütte W, Lorigan P, Reck M, Domine M, Shepherd FA, Li S, Renschler MF.

J Clin Oncol. 2014 Nov 10. pii: JCO.2013.54.5392. [Epub ahead of print]

PMID:
25385727
[PubMed - as supplied by publisher]
2.

Efficacy and safety of long-term treatment with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Dimopoulos MA, Swern AS, Li JS, Hussein M, Weiss L, Nagarwala Y, Baz R.

Blood Cancer J. 2014 Nov 7;4:e257. doi: 10.1038/bcj.2014.77.

PMID:
25382609
[PubMed - in process]
3.

Nonhematologic Toxicity of Imatinib Mesylate in Pediatric Patients With Chronic Myelogenous Leukemia: A Predominance of Musculoskeletal Pain.

Heym KM, Gressett Ussery SM, Trinkman H, Philpot LM.

J Pediatr Hematol Oncol. 2014 Nov 4. [Epub ahead of print]

PMID:
25374285
[PubMed - as supplied by publisher]
4.

Comparative Transcriptomics between Synechococcus PCC 7942 and Synechocystis PCC 6803 Provide Insights into Mechanisms of Stress Acclimation.

Billis K, Billini M, Tripp HJ, Kyrpides NC, Mavromatis K.

PLoS One. 2014 Oct 23;9(10):e109738. doi: 10.1371/journal.pone.0109738. eCollection 2014.

PMID:
25340743
[PubMed - in process]
Free PMC Article
5.

Overview of the "Epigenetic End Points in Toxicologic Pathology and Relevance to Human Health" Session of the 2014 Society of Toxicologic Pathology Annual Symposium.

Hoenerhoff MJ, Hartke J.

Toxicol Pathol. 2014 Oct 20. pii: 0192623314553475. [Epub ahead of print]

PMID:
25330923
[PubMed - as supplied by publisher]
6.

Abraxane® versus Taxol® for patients with advanced breast cancer: A prospective time and motion analysis from a Chinese health care perspective.

Dranitsaris G, Yu B, Wang L, Sun W, Zhou Y, King J, Kaura S, Zhang A, Yuan P.

J Oncol Pharm Pract. 2014 Oct 14. pii: 1078155214556008. [Epub ahead of print]

PMID:
25316611
[PubMed - as supplied by publisher]
7.

Pathogenesis, diagnosis, and management of kikuchi-fujimoto disease.

Deaver D, Horna P, Cualing H, Sokol L.

Cancer Control. 2014 Oct;21(4):313-21.

PMID:
25310212
[PubMed - in process]
Free Article
8.

Lenalidomide for Complex Regional Pain Syndrome Type 1: Lack of Efficacy in a Phase II Randomized Study.

Manning DC, Alexander G, Arezzo JC, Cooper A, Harden RN, Oaklander AL, Raja SN, Rauck R, Schwartzman R.

J Pain. 2014 Oct 2. pii: S1526-5900(14)00940-7. doi: 10.1016/j.jpain.2014.09.013. [Epub ahead of print]

PMID:
25283471
[PubMed - as supplied by publisher]
Free Article
9.

Essentials of oral oncolytics: developing a nursing reference.

Matthews J, Caprera PH.

Clin J Oncol Nurs. 2014 Oct;18(5):E88-92. doi: 10.1188/14.CJON.E88-E92.

PMID:
25253119
[PubMed - in process]
10.

Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors.

Jones RL, Kim ES, Nava-Parada P, Alam S, Johnson FM, Stephens AW, Simantov R, Poondru S, Gedrich R, Lippman SM, Kaye SB, Carden CP.

Clin Cancer Res. 2014 Sep 10. [Epub ahead of print]

PMID:
25208878
[PubMed - as supplied by publisher]
11.

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q).

Sekeres MA, Swern AS, Fenaux P, Greenberg PL, Sanz GF, Bennett JM, Dreyfus F, List AF, Li JS, Sugrue MM.

Blood Cancer J. 2014 Aug 29;4:e242. doi: 10.1038/bcj.2014.62. No abstract available.

PMID:
25171203
[PubMed - in process]
Free PMC Article
12.

Pomalidomide: Evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.

Kasserra C, Assaf M, Hoffmann M, Li Y, Liu L, Wang X, Kumar G, Palmisano M.

J Clin Pharmacol. 2014 Aug 27. doi: 10.1002/jcph.384. [Epub ahead of print]

PMID:
25159194
[PubMed - as supplied by publisher]
13.

Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.

Chamberlain P, Delker S, Pagarigan B, Mahmoudi A, Jackson P, Abbasian M, Muir J, Raheja N, Cathers B.

PLoS One. 2014 Aug 11;9(8):e103638. doi: 10.1371/journal.pone.0103638. eCollection 2014.

PMID:
25111382
[PubMed - in process]
Free PMC Article
14.

Structure of the human Cereblon-DDB1-lenalidomide complex reveals basis for responsiveness to thalidomide analogs.

Chamberlain PP, Lopez-Girona A, Miller K, Carmel G, Pagarigan B, Chie-Leon B, Rychak E, Corral LG, Ren YJ, Wang M, Riley M, Delker SL, Ito T, Ando H, Mori T, Hirano Y, Handa H, Hakoshima T, Daniel TO, Cathers BE.

Nat Struct Mol Biol. 2014 Sep;21(9):803-9. doi: 10.1038/nsmb.2874. Epub 2014 Aug 10.

PMID:
25108355
[PubMed - in process]
15.

In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone.

Ocio EM, Fernández-Lázaro D, San-Segundo L, López-Corral L, Corchete LA, Gutiérrez NC, Garayoa M, Paíno T, García-Gómez A, Delgado M, Montero JC, Díaz-Rodríguez E, Mateos MV, Pandiella A, Couto S, Wang M, Bjorklund CC, San-Miguel JF.

Leukemia. 2014 Aug 8. doi: 10.1038/leu.2014.238. [Epub ahead of print]

PMID:
25102946
[PubMed - as supplied by publisher]
16.

Effect of particle size on the speed and resolution of chiral separations using supercritical fluid chromatography.

Biba M, Regalado EL, Wu N, Welch CJ.

J Chromatogr A. 2014 Oct 10;1363:250-6. doi: 10.1016/j.chroma.2014.07.010. Epub 2014 Jul 12.

PMID:
25082525
[PubMed - in process]
17.

Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials.

Sewell F, Chapman K, Baldrick P, Brewster D, Broadmeadow A, Brown P, Burns-Naas LA, Clarke J, Constan A, Couch J, Czupalla O, Danks A, DeGeorge J, de Haan L, Hettinger K, Hill M, Festag M, Jacobs A, Jacobson-Kram D, Kopytek S, Lorenz H, Moesgaard SG, Moore E, Pasanen M, Perry R, Ragan I, Robinson S, Schmitt PM, Short B, Lima BS, Smith D, Sparrow S, van Bekkum Y, Jones D.

Regul Toxicol Pharmacol. 2014 Oct;70(1):413-29. doi: 10.1016/j.yrtph.2014.07.018. Epub 2014 Jul 29.

PMID:
25078890
[PubMed - in process]
Free Article
18.

The interaction between checkpoint kinase 1 (Chk1) and the minichromosome maintenance (MCM) complex is required for DNA damage-induced Chk1 phosphorylation.

Han X, Aslanian A, Fu K, Tsuji T, Zhang Y.

J Biol Chem. 2014 Aug 29;289(35):24716-23. doi: 10.1074/jbc.M114.575035. Epub 2014 Jul 21.

PMID:
25049228
[PubMed - in process]
19.

Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53.

Fecteau JF, Corral LG, Ghia EM, Gaidarova S, Futalan D, Bharati IS, Cathers B, Schwaederlé M, Cui B, Lopez-Girona A, Messmer D, Kipps TJ.

Blood. 2014 Sep 4;124(10):1637-44. doi: 10.1182/blood-2014-03-559591. Epub 2014 Jul 2.

PMID:
24990888
[PubMed - indexed for MEDLINE]
20.

The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.

Liu Y, Zhou S, Wan Y, Wu A, Palmisano M.

Br J Clin Pharmacol. 2014 Nov;78(5):1050-7. doi: 10.1111/bcp.12448.

PMID:
24962564
[PubMed - in process]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk